- Home
- RMAX vs SAVA Comparison
RMAX vs SAVA Comparison
Compare RMAX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | SAVA |
|---|---|---|
| Founded | 1973 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 156.5M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMAX | SAVA |
|---|---|---|
| Price | $7.61 | $1.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $5.00 |
| AVG Volume (30 Days) | 137.3K | ★ 1.0M |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $292,931,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | $12.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.90 | $1.15 |
| 52 Week High | $10.97 | $4.98 |
Technical Indicators
Market Signals| Indicator | RMAX | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 30.54 |
| Support Level | $7.50 | $2.15 |
| Resistance Level | $7.71 | $3.32 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 9.91 | 1.10 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.